The Liver Forum

Advancing regulatory science for NAFLD/NASH by providing independent and neutral venue for ongoing multi-stakeholder dialogue.

[The Liver Forum @LiverForum]

Our latest, 'Attribution of NASH as Etiology of Cirrhosis for Clinical Trials Eligibility' in latest issue of @AGA_Gastro - 👏👏👏 congratulations to authors and all working group members!
https://t.co/RBV93oSxtQ

[The Liver Forum @LiverForum]

New Positions Open!
https://t.co/k8XoF8hPD4

[Fatty Liver Foundation @LiverSaver]

October is Liver Awareness Month. Join us TODAY starting at 3:45 pm ET as FLF joins @MadrigalPharma to ring the @Nasdaq closing bell to increase awareness of the need for more screening & testing to improve diagnosis & staging of #NAFLD #NASH→https://t.co/w9jsxiqsmy #LiverHealth

[Wayne Eskridge @WayneEskridge1]

ELF was just approved as a blood test for fibrosis by @US_FDA and this is an important step in the efforts to develop better tools for diagnosing advanced liver disease and getting away from liver biopsy➡️https://t.co/mtvgF96Em4
#NAFLD #NASH #liverhealth #patientadvocacy #blog

[Mazen Noureddin, MD, MHSc @NoureddinMD]

ELF by @Siemens has been approved by the FDA as a prognostic maker to be used in #NASH. #livertwitter 👇🏼@AlkhouriNaim @schattenbergJ @KathleenCoreyMD @DrLoomba @DrMTLong @RomaLevy @NASH_and_coffee @AASLDtweets @drmoutaz @HD3vedi @surfing_NASH

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

Ani Kardashian on food insecurity & assoc w/all-cause mortality in US adults w/ #NAFLD #ILC2021: food insecurity is ltd or uncertain availability of nutritionally adequate foods or inability to acquire foods in socially acceptable way. 35 million (18 million in USA) experience it

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

@AniKardashianMD Food insecurity in adults with NAFLD associated with all-cause mortality after adjustment for a number of factors #ILC2021

[Echosens @Echosens]

Join us today at #ILC2021 for a live webinar with Prof. Boursier and Prof. Noureddin on #FibroScan-based Scores: Agile 3+, Agile 4, Fast™, to identify early and accurately patients at risk of developing cirrhosis and liver-related complications. https://t.co/qY04Ms79h8
#NAFLD

[Fatty Liver Foundation @LiverSaver]

June 10th is International #NASHDay. Join advocates & partners from across the🌐as we spread awareness about this serious #liverdisease that is on the rise. Together we can make our voices heard! Join the conversation🙌#NASHDay⮕https://t.co/yxJboTAUGK #NAFLD #NASH @GlobalLiver

[Wayne Eskridge @WayneEskridge1]

I don't know that this is news really but I was one of the patient advocates interviewed for an extensive article in @PharmaVOICE about the need for industry to include patients in the process of drug development⮕https://t.co/AnS6azw3Rd
#NASH #NAFLD #PatientAdvocacy

[The Liver Forum @LiverForum]

Nonalcoholic fatty liver disease (#NAFLD) is the most common #ChronicLiverDisease (#CLD) in children worldwide.

Our very own Dr. Veronica Miller & the @LiverForum Pediatric Working Group explore research for a “silver bullet” treatment.

https://t.co/WQNSvr6C9Q

[UC Berkeley Online MPH @BerkeleyMPH]

A new paper from BPH's Dr. Veronica Miller & the @LiverForum Pediatric Working Group combs through the research for a “silver bullet” treatment for nonalcoholic fatty liver disease (#NAFLD), the most common #ChronicLiverDisease in children worldwide. https://t.co/e5G8AovHyy

[EASLnews @EASLnews]

Today is #WorldCancerDay, 4 Feb.

Did you know? #Livercancer is the 3rd-leading cause of cancer-related deaths🌐worldwide. What are the main causes of liver cancer?

➡️https://t.co/KBbGVsBFGo

To find out more, consult our new infographic, Liver Cancer Explained.
@EASLedu

[FDA Drug Information @FDA_Drug_Info]

INDUSTRY STAKEHOLDERS: Get email updates from the CDER Small Business and Industry Assistance (SBIA) program to learn about:

🟠 Industry news
🟠 New guidances
🟠 Meetings & conferences
🟠 Educational tutorials
🟠 Webinars
🟠 And more!

Sign up here: https://t.co/0p0VED2pMw

[FDA Drug Information @FDA_Drug_Info]

The Translational Science Interagency Fellowship sponsored by FDA & @ncats_nih_gov is looking for individuals interested in bringing safe & effective drugs, regimens, and devices from the bench to the bedside as quickly as possible.

Apply now: https://t.co/vgfx9ivOSp

[The Liver Forum @LiverForum]

We are hiring! Know anyone with a background in project management, research, & liver disease? Share our job announcement: https://t.co/12MveIByHT

[Fatty Liver Foundation @LiverSaver]

Don't miss this #webcast on January 29th as the @US_FDA will provide a summary of the agency's current thinking on the published draft guidance📄 & regulatory pathways for development of drugs for treatment of #NASH👉https://t.co/tJqrCtrUJF

[FDA Drug Information @FDA_Drug_Info]

Learn about FDA’s table of surrogate endpoints that provides transparency, coherency, and consistency for stakeholders seeking to design effective drug development programs in the latest #CDERImpactStory: https://t.co/mStup6052u

[EASLnews @EASLnews]

Today we’re launching the International Liver Congress™ 2021 https://t.co/x7uFDwD2MJ Clear your agendas for Wed to Sat, 23–26 June. Prepare to send in your abstracts & register for #EASL’s flagship #ILC2021 on beating liver disease together. Share this with your peers! @EASLedu

[NASH-TAG Conference @NashTagConf]

DATES HAVE CHANGED! Register for #NASHTAG 2021 today. https://t.co/ViX8YlXGyb